Tara Mitchell, MD
Hematology & Oncology · Philadelphia, PANPI 1982850558
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $71,252 of the $88,841 with a category attached, or 80.2%. Merck accounts for 66.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $32,886 and has fallen 78.4% since, to $7,100 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $1124.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$59K
- E.r. Squibb & Sons, L.L.C.$19K
- Array Biopharma Inc$7K
- Incyte Corporation$4K
- Iovance Biotherapeutics, Inc.$85
- Seagen Inc.$14
Across 582 payments — averaging $5355.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.9M
- Incyte Corporation$1.2M
- E.r. Squibb & Sons, L.L.C.$40K
- Genentech, Inc.$12K
- Organon$6K
What the payments were for
- Consulting fees$71,25280%
- Speaking & faculty fees$6,4687%
- Travel & lodging$9,71811%
- Food & beverage$1,4032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 47 | $58,967 |
| E.r. Squibb & Sons, L.L.C. | 19 | $18,733 |
| Array Biopharma Inc | 8 | $7,410 |
| Incyte Corporation | 3 | $3,633 |
| Iovance Biotherapeutics, Inc. | 1 | $85 |
| Seagen Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,841 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 11 | $68 |
| Levothyroxine Sodium | 14 | $57 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.